Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278055 · ClinicalTrials.gov registry record · Phase 2
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study of Pain and Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT02278055 is a Phase 2 study of Pain and Metastatic Prostate Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02278055, a Phase 2 study of Pain and Metastatic Prostate Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
Conditions Studied
Interventions
- DRUG Radium-223
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
- New York Presbyterian Hospital-Weill Medical College of Cornell University - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-10-08 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278055
The ClinicalTrials.gov registry entry for NCT02278055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Radium-223 is the first listed.
NCT02278055 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02278055 about?
NCT02278055 is a clinical study titled "Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
What is the current status of trial NCT02278055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-10-08. Estimated completion is 2022-02-02.
What conditions does trial NCT02278055 study?
This clinical trial studies the following conditions: Pain, Metastatic Prostate Cancer.
What interventions are being tested in trial NCT02278055?
The interventions under investigation include: Radium-223 (DRUG).
Who is sponsoring clinical trial NCT02278055?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02278055 being conducted?
This trial has 3 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.